ITM Isotope Technologies Munich SE is a leading biotechnology and radiopharmaceutical group dedicated to transforming cancer treatment. With a focus on targeted diagnostic and therapeutic radiopharmaceuticals, they develop, produce, and globally supply innovative solutions for cancer patients. Since their establishment in 2004, ITM and its subsidiaries have built a robust global supply network and manufacturing infrastructure for their groundbreaking medical radioisotopes and generator platforms.

These advancements enable the next generation of targeted cancer diagnostics and therapies. ITM's Precision Oncology Pipeline includes a range of targeted treatments in various stages of clinical development to address different types of cancers. Their portfolio encompasses neuroendocrine tumors, glioblastoma, prostate cancer, ovarian cancer, NSCL adenocarcinoma, osteosarcoma, and bone metastases.

One of their most promising candidates is n. c. a.

177 Lu-edotreotide, a Targeted Radionuclide Therapy specifically designed for neuroendocrine tumors. This treatment is currently undergoing international pivotal phase III clinical trials, COMPETE and COMPOSE. Through scientific collaborations, ITM aims to significantly improve treatment outcomes and quality of life for cancer patients while reducing side effects and improving healthcare economics.

ITM Isotope Technologies Munich SE is devoted to revolutionizing Precision Oncology with their cutting-edge solutions